Life sciences company EKF Diagnostics Holdings plc (AIM: EKF) has acquired technology assets from Sweden-based Beep Insights AB, including its iOS and Android application designed for real-time glucose and lactate tracking in sports performance monitoring.
The Beep Insights Technology integrates data from Bluetooth-connected wearables with biomarker tracking to deliver personalised training metrics. The acquisition is expected to enhance EKF's existing Sports Performance portfolio, particularly its Lactate Scout Sport handheld analyser, which is already compatible with the application.
EKF has collaborated with Beep Insights and its chief executive officer, Peter Alex, to integrate the software and improve accessibility in determining lactate threshold and optimising training outcomes. Following completion of the transaction, Alex will join EKF to support further development, including the application of artificial intelligence in performance training.
Headquartered in Penarth, Wales, EKF Diagnostics is a global diagnostics business specialising in point-of-care analysers for haematology and diabetes. The company operates manufacturing sites in the US and Germany and serves customers in more than 120 countries.
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cirius Therapeutics introduces gestational diabetes initiative
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval